Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roug | Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roughly tripled under antitrust law.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen…

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.

Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…

Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its…